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https://doi.org/10.1016/j.celrep.2021.109521SUMMARYThe gut metabolite composition determined by the microbiota has paramount impact on gastrointestinal
physiology. However, the role that bacterial metabolites play in communicating with host cells during inflam-
matory diseases is poorly understood. Here, we aim to identify the microbiota-determined output of the pro-
inflammatory metabolite, succinate, and to elucidate the pathways that control transepithelial succinate ab-
sorption and subsequent succinate delivery to macrophages. We show a significant increase of succinate
uptake into pro-inflammatory macrophages, which is controlled by Na+-dependent succinate transporters
in macrophages and epithelial cells. Furthermore, we find that fecal and serum succinate concentrations
were markedly augmented in inflammatory bowel diseases (IBDs) and corresponded to changes in succi-
nate-metabolizing gut bacteria. Together, our results describe a succinate production and transport pathway
that controls the absorption of succinate generated by distinct gut bacteria and its delivery into macro-
phages. In IBD, this mechanism fails to protect against the succinate surge, which may result in chronic
inflammation.INTRODUCTION
The epithelium of the gastrointestinal (GI) tract absorbs nutrients
and minerals but also acts as the main barrier that protects
against the penetration of pathogens. Damage to the epithelium
may lead to severe infections by pathogens, inflammation, loss
of minerals, and hampered metabolite absorption and secretion.
This occurs in several pathologies, most notably, inflammatory
bowel diseases (IBDs), namely, Crohn’s disease (CD) and ulcer-
ative colitis (UC). Although the etiology of IBD has not been fully
established, it is known that it is associated with impaired epithe-
lial barrier function and activated immune cells in the gut mucosa
that produce excessive amounts of pro-inflammatory mediators
(Onizawa et al., 2009; Plevy et al., 1997; Schmitz et al., 1999).
Current treatments for active IBD include anti-inflammatory
drugs, immunomodulators, and/or biological agents (Colombel
et al., 2010; Nielsen and Ainsworth, 2013).
Implicated in the pathogenesis of several diseases, including
IBD, obesity, and some allergic disorders, is an imbalance in
the intestinal microbiota, termed ‘‘dysbiosis’’ (DeGruttola et al.,This is an open access article und2016). Therefore, characterization of the gut microbiome and
its alteration in diseases have emerged as areas of intensive
research. It has thus been shown that microbial-secretedmetab-
olites regulate colonic homeostasis by stimulating specific re-
ceptors (Smith et al., 2013). Metabolite-sensing receptors and
metabolite transport proteins are highly expressed both on the
gut epithelia and also on macrophages (Niess and Adler, 2010;
Niess et al., 2005). Nevertheless, the role that metabolites pro-
duced by the gut microbiome play in the pathogenesis of IBD
is less investigated.
On one hand, the metabolic intermediate, succinate, has
been shown to play a key role in intestinal homeostasis and en-
ergy metabolism, but on the other hand, succinate also acts as
a pro-inflammatory metabolite. Notably, cytoplasmic succinate
accumulation stabilizes hypoxia-inducible factor 1a (HIF-1a),
shifting macrophages to glycolysis and to a pro-inflammatory
state (Tannahill et al., 2013). In mammalian cells, the cyto-
plasmic succinate levels are determined by mitochondrial suc-
cinate production in the TCA cycle, driven by glutamine-depen-
dent anaplerosis. However, extracellular succinate uptakeCell Reports 36, 109521, August 10, 2021 ª 2021 The Authors. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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transporters is another pivotal source for intracellular succinate.
It has been previously shown that succinate uptake into mouse
intestinal tissue is indeed Na+ dependent and involves the
orchestrated function of SLC13 transporters (Browne et al.,
1978; Ohana et al., 2013; Pajor, 1995). In addition, the major
succinate transporter, SLC13A2, is strongly inhibited by the
SLC26A6 transporter through interaction. Thus, the SLC13/
SLC26 complex strictly regulates succinate homeostasis (Kha-
maysi et al., 2019; Ohana et al., 2013). Hence to reabsorb suc-
cinate across epithelial cell membranes, SLC13 transporters
mediate succinate influx, and the organic anion transporters
(OATs) mediate succinate efflux via an organic anion/carboxylic
acid exchange mechanism (Emami Riedmaier et al., 2012). For
example, the major basolateral transporters that mediate succi-
nate extrusion in the proximal tubule epithelia are the OAT 1
and 3 (Kojima et al., 2002; Lungkaphin et al., 2006). The OAT
10 transporter mediates succinate extrusion via the apical
membrane and was shown to express in the kidney and colon
(Wang and Sweet, 2013). In the colorectal Caco-2 cells, succi-
nate influx was shown to be mediated mainly by SLC13A2,
which is highly selective to succinate, and also by SLC13A5,
which is more selective to citrate than to succinate (Weera-
chayaphorn and Pajor, 2008). An OAT transporter, likely
OAT4, that mediates the transport of methylsuccinate, but not
succinate, was also found in Caco-2 cells.
Succinate acts as a pivotal metabolic signaling molecule via
stimulation of the succinate-specific G protein-coupled recep-
tor, succinate receptor (SUCR1, GPR91, or SUCNR1). The
SUCNR1 has been shown to be expressed in several tissues
and cells, including hepatic stellate cells (De Minicis et al.,
2007), human monocyte-derived dendritic cells (MoDCs), and
in the epithelia of the intestine and kidney, where SUCNR1 stim-
ulation regulates SLC13, but not OAT, function (Khamaysi et al.,
2019; Toma et al., 2008). The expression of SUCNR1 is
increased in pro-inflammatory macrophages (Littlewood-Evans
et al., 2016), and several studies have reported that SUCNR1
stimulation by elevated extracellular succinate amplifies the
pro-inflammatory state in macrophages (Littlewood-Evans
et al., 2016) and in dendritic cells (Rubic et al., 2008). Another
study showed that immature MoDCs (iMoDCs) migrate in
response to succinate in a dose-dependent manner, with
Sucnr1–/– mice exhibiting impaired migration of dendritic cells
and a diminished immune response (Rubic et al., 2008). In neural
stem cells, SUCNR1 stimulation activates scavenging of the pro-
inflammatory succinate, thus resulting in lower succinate to
reduce inflammation (Peruzzotti-Jametti et al., 2018). Intestinal
tuft cells utilize SUCNR1 to detect succinate secreted by bacte-
rial and parasitic infection to activate a secondary immune
response (Lei et al., 2018). In contrast, a more recent study sug-
gests that SUCNR1 stimulation in adipose tissue-resident mac-
rophages may trigger an anti-inflammatory response (Keiran
et al., 2019). Together, these studies indicate that elevated intra-
cellular succinate is an obligatory pro-inflammatory signal. How-
ever, although extracellular succinate generally amplifies pro-in-
flammatory responses, under specific conditions it may also act
as an anti-inflammatory signal. Remarkably, in IBD, SUCNR1
promotes inflammation, because Sucnr1 deletion in mice pro-2 Cell Reports 36, 109521, August 10, 2021tects against symptoms of induced colitis and intestinal fibrosis
(Macias-Ceja et al., 2019).
A particular aspect of succinate homeostasis is the role of
altered microbiota-produced succinate transport in sustaining
inflammation, which is the main focus of our study. Elevated
cytoplasmic succinate concentrations facilitate pro-inflamma-
tory macrophage polarization and plasticity. Hence trans-
porter-mediated absorption of luminal succinate may play a
key role in either triggering or maintaining the GI symptoms of
IBD and related disorders. Therefore, we asked: what is the
role of transepithelial absorption of microbiota-generated succi-
nate in controlling succinate delivery into macrophages in IBD?
RESULTS
Succinate uptake into macrophages is augmented by
lipopolysaccharides/interferon g (LPS/IFNg) treatment
A succinate-rich environment can potentially contribute to
chronic inflammation, because both intracellular and extracel-
lular succinate induce and maintain the pro-inflammatory state
of macrophages (Tannahill et al., 2013). To determine whether
succinate uptake into macrophages is affected by macrophage
polarization, we monitored succinate uptake into three different
macrophage populations of either primary bone marrow-derived
macrophages (BMDMs) or RAW264.7 cell line, as indicated in
Figure 1. Our results show that succinate uptake into LPS/
IFNg-treated pro-inflammatory macrophages is significantly
elevated in a time-dependent manner. In fact, the uptake
increased as high as 5.5-fold in LPS/IFNg-treated BMDMs that
were cultured in macrophage colony-stimulating factor (M-
CSF) media, compared with naive and interleukin (IL)-4/IL-13-
treated cells (Figure 1A, 45 min of uptake). The uptake into
BMDMs that were cultured in granulocyte-macrophage colony-
stimulating factor (GM-CSF) showed a 1.5-fold increase after
45min of incubationwith succinate (Figure 1B). The inflammatory
state of the M-CSF-treated macrophage culture was confirmed
by nitric oxide (NO) secretion assay that showed a dramatic
elevation of NO secretion in LPS/IFNg-treated macrophages
comparedwith the naive and IL-4/IL-13-treated populations (Fig-
ure1C). Inaddition,wemonitoredCD11b+andF4/80 (FigureS1A)
or CD80 (Figure S1B) expression by flow cytometry, as well as
CD206 (Figure S1C) and IL-1b (Figure S1D) expression by west-
ern blot analysis, that further verified the inflammatory state of the
macrophage cultures that were described in Figure 1. In
RAW264.7 cells, we measured an almost 3-fold increase in suc-
cinate uptake compared with the naive or the anti-inflammatory
IL-4/IL-13-treated populations (Figure 1D) under conditions
similar to those described in Figure 1B. Because elevated cyto-
plasmic succinate re-programs macrophages to the pro-inflam-
matory state (Tannahill et al., 2013), we measured the effect of
extracellular succinate on the inflammatory state by monitoring
NO secretion in the presence or absence of succinate. To atten-
uate intracellular succinate production,we stimulated themacro-
phages for 16 h in media containing LPS/IFNg and extracellular
succinate. Then, the culture was washed and incubated for
50 h in the absence of L-glutamine with or without succinate, as
indicated. We found that in the presence of extracellular succi-
nate in the media, NO secretion was progressively elevated up
Figure 1. The Na+-dependent uptake of suc-
cinate into LPS/IFNg-treated cells is higher
than the uptake into other macrophage pop-
ulations
(A and B) Succinate uptake measured in treated
BMDMs.
Notably, LPS/IFNg-treated macrophages show
higher succinate uptake compared with naive and
IL-4/IL-13-treated macrophages.
(C) The results in (A and B) correlate with elevated
NO secretion (C) in the pro-inflammatory popula-
tion.
(D) Similarly, succinate uptake was increased in
LPS/IFNg-treated RAW264.7 cell culture.
(E) RAW264.7 cells were stimulated in a glutamine-
containing media in the presence of 5 mM Na+-
succinate. Subsequently, the cultures were
washed and incubated in glutamine-free media in
the presence (+succinate) or absence (succinate-
free) of succinate, and NO concentrations were
monitored at different time points.
(F and G) Succinate uptake was monitored in the
presence or absence of Na+ in either BMDMs (F) or
RAW264.7 cells (G), as indicated in the figure.
Data are shown as means ± SEM. Statistical sig-
nificance was assessed either with t test or one-
way ANOVA followed by Tukey’s or Holm-Sidak’s
post-test. *p < 0.05, **p < 0.01, ***p < 0.001.
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levels monitored in succinate-free media (Figure 1E). This sug-
gests that extracellular succinate uptake exacerbates the inflam-
matory function of macrophages over time. To determine
whether succinate uptake into macrophages is mediated by the
Na+-dependent SLC13 transporters, we monitored BMDM suc-
cinate uptake in the presence or absence of Na+ (Figure 1F).
We found that background succinate uptake in naive cells was
Na+ independent, while the increased uptake in LPS/IFNg-
treatedcellswasdramatically reduced in theabsenceofNa+ (Fig-
ure 1F). This suggests that a significant portion of succinate
uptake by pro-inflammatory macrophages is Na+ dependent.
Finally, we found a 30% decrease in the uptake of succinate
into LPS/IFNg-treated RAW264.7 cells that were incubated in aC
Na+-free solution compared with that
monitored in Na+-containing solution (Fig-
ure 1G). These findings suggest that the
uptake of succinate into pro-inflammatory
macrophages is significantly elevated
compared with either naive or anti-inflam-
matory polarized macrophages. The
elevated succinate uptake into macro-
phages is mediated by a Na+-dependent
transport mechanism,most likely by a sin-
gle or several members of the SLC13 fam-
ily that act as Na+-dependent succinate/
citrate transporters, namely, SLC13A2,
SLC13A3, or SLC13A5.
Therefore, we aimed to identify how
the SLC13 transporter-mediated succi-
nate uptake into macrophages is regu-lated. We have previously shown that stimulation of SUCNR1
by succinate regulates both SLC13A2 and SLC13A3, which
are more selective to succinate but also mediate citrate trans-
port (Khamaysi et al., 2019). Therefore, to discern SUCNR1
stimulation from SLC13 transport function, we monitored cit-
rate uptake into LPS/IFNg-treated RAW264.7 cells in the pres-
ence or absence of either 250 mM succinate or the SLC13A5-
specific inhibitor, BI01383298 (10 mM) (Higuchi et al., 2020).
Our results in Figure 2A indicate that the addition of 250 mM
succinate elevated citrate uptake into stimulated macro-
phages, likely by stimulating SUCNR1, the expression of
which is augmented in LPS/IFNg-stimulated macrophages
(Figure 2B; Littlewood-Evans et al., 2016). Nonetheless, the
SLC13A5 inhibitor had no effect on citrate uptake, suggestingell Reports 36, 109521, August 10, 2021 3
Figure 2. The Na+-dependent succinate up-
take by macrophages is likely mediated by
an SLC13 transporter and regulated by
SUCNR1 and SLC26A6
(A) Citrate uptake was measured in either naive- or
LPS/IFNg-treated RAW264.7 cells. Notably, the
SLC13A5 inhibitor (inh) did not affect citrate uptake,
which was increased by application of 250 mM suc-
cinate (succ), potentially because of stimulation of
SUCNR1, which is significantly elevated in LPS/
IFNg-treated cells.
(B) Western blot analysis of SUCNR1 expression in
either naive or LPS/IFNg-treated RAW264.7 macro-
phages.
(C) The uptake of succinate was monitored using a
radiolabeled succinate flux assay in peritoneal mac-
rophages that were isolated from either WT or
SLC26A6/ mice.
(D–F) The regulatory effect of SLC26A6 on SLC13A3-
mediated succinate uptake monitored in RAW264.7
cells (D) in Xenopus oocytes (E) or in HEK293 cells (F)
expressing SLC13A3 and SLC26A6, as indicated.
Data are shown as means ± SEM. Statistical signifi-
cance was assessed with either t test or one-way
ANOVA followed by Tukey’s post-test. *p < 0.05,
**p < 0.01, ***p < 0.001.
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dent succinate transport in macrophages. Previous studies
have indicated that the Slc13a3 gene expression is highly
regulated during mouse macrophage plasticity (Jablonski
et al., 2015). These findings suggest that SLC13A3 may play
a key role in mediating and regulating succinate transport in




which is expressed in macrophages (Figure S1E; Noubade
et al., 2014), was shown to interact with SLC13 transporters to
inhibit succinate uptake (Khamaysi et al., 2019, 2020; Ohana
et al., 2013). As shown in Figure 2C, succinate uptake into peri-
toneal macrophages was 20% higher in slc26a6/ mice
compared with wild-type (WT).4 Cell Reports 36, 109521, August 10, 2021To test whether SLC26A6 regulates
succinate uptake via SLC13A3, we ex-
pressed SLC13A3 and SLC26A6 either
alone or together in RAW264.7 macro-
phages (Figure 2D) in Xenopus oocytes
(Figure 2E), as well as in HEK293 cells
(Figure 2F), and monitored succinate up-
take and currents. In agreement with the
results in Figure 2C, we found that
SLC26A6 significantly inhibits SLC13A3
activity in all cells.
Jointly, our results in Figures 1 and 2
indicate that the Na+-dependent uptake
of succinate into pro-inflammatory mac-
rophages is significantly elevated
compared with either naive or anti-inflam-matory polarized macrophages. In addition, SLC13A3-mediated
succinate uptake and its regulation by SUCNR1 or SLC26A6
perpetuate the pro-inflammatory state of macrophages by
elevating cytoplasmic succinate concentrations (Figure 1F).
The intestinal tissuemediatesNa+-dependent succinate
uptake to control succinate delivery to macrophages
In the gut, transepithelial succinate absorption is mediated by
the SLC13 family of succinate transporters, most notably, the
apical transporters, SLC13A2 and SLC13A5, as well as the ba-
solateral transporter, SLC13A3 (Markovich and Murer, 2004;
Pajor, 2006). These members of the SLC13 family of trans-
porters mediate Na+-dependent succinate and citrate trans-
port. To demonstrate the pivotal role of SLC13 transporters in
mediating transepithelial succinate absorption, we monitored
Figure 3. Transepithelial succinate absorp-
tion and delivery to macrophages are Na+
dependent
(A) 14C-succinate uptake into Caco-2 monolayer is
significantly elevated in the presence of 1 mM
succinate and extracellular Na+, suggesting slc13
transporter-mediated influx.
(B) Transepithelial transport rates via Caco-2 cell
Transwell monolayer are dramatically elevated in
the presence of extracellular Na+.
(C) Succinate was administered to the apical
chamber of a Caco-2 monolayer Transwell culture
in the presence or absence of Na+, and succinate
concentrations were monitored in macrophages
that were co-cultured at the basolateral chamber.
(D and E) In addition, the basolateral media were
collected and added to separately cultured LPS/
IFNg-treated RAW264.7 macrophages (D) or
BMDMs (E) to measure succinate uptake.
(F) Caco-2 cells were transfected with either
SLC13A2 or SLC26A6, as indicated, and succinate
uptake was monitored.
Data are shown as means ± SEM. Statistical sig-
nificance was assessed either with t test or one-
way ANOVA followed by Tukey’s post-test. *p <
0.05, **p < 0.01, ***p < 0.001.
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(Caco-2) that was shown to express specific SLC13s (Weera-
chayaphorn and Pajor, 2008). As shown in Figure 3A, we moni-
tored a time-dependent increase in succinate uptake into the
epithelial cells in the presence of sodium compared with its
absence, suggesting that SLC13 members mediate succinate
influx in the human intestinal epithelial cells. To determine
transepithelial uptake of succinate, we utilized a culture of
Caco-2 cells monolayer in Transwell inserts. We applied succi-
nate in the presence of 14C-succinate to the apical chamber
and monitored succinate concentrations at the basolateral
chamber (as described in the STAR Methods). As shown in Fig-
ure 3B, the transepithelial succinate uptake rate is increased
about 5.4-fold in the presence of Na+. Next, we co-cultured
Caco-2 (apical) and LPS/IFNg-treated macrophages (basolat-
eral) in a Transwell system, applied succinate to the apical
chamber, and monitored succinate uptake into the basolateral
macrophages (Figure 3C). In addition, we collected the basolat-C
eral media and applied it to LPS/IFNg-
treated RAW264.7 (Figure 3D) and
BMDMs (Figure 3E) cultured separately.
Our results suggest that transepithelial
succinate uptake and basolateral succi-
nate concentrations are significantly
higher in the presence of Na+ compared
with those in the absence of Na+. Conse-
quently, succinate uptake into LPS/IFNg-
treated macrophages, which reside in
the basolateral side, is also higher (Fig-
ure 3C). Finally, we transfected Caco-2
cells with SLC13A2, SLC26A6, or
SLC13A2 and SLC26A6 together; moni-tored succinate uptake (Figure 3F); and found that SLC26A6 in-
hibits the SLC13A2-mediated succinate uptake.
Together, our results from the gut epithelia-macrophages
model system indicate that epithelial succinate transporters
mediate succinate delivery to macrophages from the gut lumen,
as well as succinate uptake by macrophages, to modulate
inflammation.
The gene expression of proteins that inhibit epithelial
succinate uptake and facilitate succinate clearance is
upregulated in IBDs
In epithelia, the SLC26 transporters, SLC26A3 and SLC26A6,
as well as SUCNR1 stimulation, inhibit succinate uptake, while
the basolateral SLC13A3 mediates succinate clearance (Kha-
maysi et al., 2019; Ohana et al., 2013). Remarkably, genetic
variation in SLC26A3 was associated with IBD and UC in
genome-wide association studies (GWASs) (Asano et al.,
2009; Liu et al., 2015). To begin assessing the contribution ofell Reports 36, 109521, August 10, 2021 5
Figure 4. The expression of determinants
that either inhibit succinate uptake or
mediate succinate clearance in intestinal
and colon tissues of IBD patients
(A and B) Representative images of immunohisto-
chemistry analysis (A) and summary (B) of
SUCNR1 protein expression in the intestine of
either healthy conrol (HC), Crohn’s disease (CD), or
ulcerative colitis (UC) patients. SUCNR1 expres-
sion was detected in epithelial cells and in the
lamina propria (arrows).
(C) The gene expression of SUCNR1 in colon tis-
sues of HCs, CD patients, or UC patients.
(D and E) Representative images of immunofluo-
rescence analysis (D) and summary (E) of SLC26A6
protein expression (green) in the intestine of HCs,
CD patients, or UC patients. SLC26A6 expression
was mainly detected in epithelial cells (arrows).
Red arrows and blue arrows indicate the apical
side of epithelial cells and macrophages, respec-
tively. Nuclei were counterstained with DAPI (blue).
(F–H) The gene expression of SLC26A6 (F),
SLC26A3 (G), and SLC13A3 (H) was monitored in
colon tissues of HCs, CD patients, or UC patients,
as indicated. The transcript levels were quantified
by real-time qRT-PCR.
Data are shown as means ± SEM. Statistical sig-
nificance was assessed using one-way ANOVA
Kruskal-Wallis test followed by Dunn’s post-test.
*p < 0.05, **p < 0.01.
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and gene expression of transporters that control succinate ho-
meostasis in intestinal and colon tissue biopsies from either
healthy control subjects (HCs), CD patients, or UC patients
(Figure 4). We found that the gene expression of SUCNR1 (Fig-
ures 4A–4C) was upregulated in the intestine and whole colon
of patients with CD and UC, as indicated. However, although
protein expression of SLC26A6 in the intestine is reduced in
UC and CD patients (Figures 4D and 4E), the gene expression
of SLC26A6 in the colon was elevated (Figure 4F). We also
monitored the gene expression of SLC26A3 (Figure 4G) and
SLC13A3 (Figure 4H). We found that both genes were upregu-
lated in the colon of patients with CD and UC, with the excep-
tion of SLC26A3 expression that was changed in UC only, in
agreement with the GWAS. This indicates that in our cohort
of IBD patients, the gut tissue expression of genes, which6 Cell Reports 36, 109521, August 10, 2021encode for proteins that function to lower
succinate absorption and elevate succi-
nate clearance, is increased, most likely
as a protective mechanism to prevent
the excessive surge of the pro-inflamma-
tory succinate.
Succinate is elevated in the feces
and serum of IBD patients and in
samples from an IBD mouse model
To test whether the impaired epithelial
succinate transport pathway fails to con-
trol succinate homeostasis in IBD, wecollected serum from HCs and from patients with CD or UC
and measured succinate concentrations. We found that serum
succinate concentrations were significantly increased in patients
with either CD or UC (Figure 5A). To identify whether the elevated
serum succinate originates from an increase of succinate in the
gut, we measured succinate concentrations in human and
mouse fecal biospecimens collected from either IBD patients
or mice with dextran sulfate sodium (DSS)-induced colitis and
compared those with HCs. Indeed, the succinate levels were
significantly increased in the feces of IBD patients (Figure 5B)
and mice with DSS-induced colitis (Figure 5C) compared with
controls. These findings suggest that in IBD, the gut tissue is
exposed to high levels of succinate in the lumen and circulation.
This may stem from lower SLC26A6 expression in the intestine
(Figure 4D and 4E), because SLC26A6 inhibits SLC13A2-medi-
ated succinate transport in epithelial cells (Figure 3F). Yet,
Figure 5. Succinate concentrations are elevated in the serum and
fecal specimens of IBD patients and a mouse model of UC
Wemeasured succinate concentrations in the serum of human samples using
gas chromatography time-of-flight mass spectrometry (GC-TOF-MS),variable
importance plot (VIP) > 1.0.
(A) Panel depicts the mean and distribution of serum succinate levels in either
CD or UC. Data are shown as means ± SEM. *p < 0.05.
(B and C) In addition, we monitored fecal succinate concentrations in human
samples (B) and in mouse samples (C).
Data are shown as means ± SEM. Statistical significance was assessed either
using t test for two-group comparison or using one-way ANOVA followed by




OPEN ACCESSelevated expression of other genes and proteins that protect
from the succinate surge (Figure 4) fails to prevent elevated suc-
cinate absorption.
The microbiota of UC patients and the mouse model are
enriched with succinate-producing bacteria and
impoverished of succinate-consuming bacteria
Elevated succinate in IBD may be a result of changes in the
composition of specific bacteria that metabolize succinate in
the gut or increased invasion of these microbes into the gut
wall. Hence we investigated the microbiome using 16S rRNA
gene pyrosequencing of feces and colon tissues from HC and
IBD patients. Beta-diversity (PCoA) and alpha-diversity (Shannon
index, Chao1 index, and Simpson index) showed a distinct clus-
tering in the microbiome of HCs and IBD patients (Figures S2A
and S2B and statistical analysis in Figure S3, tables 1 and 2,
respectively) and reduced diversity in IBD samples (Figures S2C
and S2D), as previously reported (Sheehan et al., 2015). We also
identified the distinct feature of IBD that indicated a lower abun-
dance of Firmicutes and higher abundance of Proteobacteria
and Bacteroidetes compared with HCs (Figures S2E and S2F).
We tested the abundance of succinate-producing bacteria spe-cies and found that B. fragiliswas significantly increased in colon
tissues of UC patients comparedwith HCs (Figure 6A). Moreover,
we observed high abundance of the major succinate producer,
B. vulgatus, in the tissue of both DSS- and TNBS-treated
mice (Figure 6B). Strikingly, the abundance of the succinate-
consuming bacteriaP. succinatutenswas significantly decreased
in thehuman tissueofCDpatients (Figure6C), andwemeasureda
similar trend for the succinate consumer P. faecium (Figure S4).
Markedly, we detected high abundance of succinate-consuming
bacteria in only a few healthy individuals, while the abundance of
thesebacteria in all IBDpatientswaseither negligible or undetect-
able. The abundance of other succinate-producing/consuming
bacterial specieswasnot significantly changed in eitherCD tissue
samplesor fecal samplesof IBDpatients andmicecomparedwith
HCs (Figures S4 and S5). Other minor succinate-consuming bac-
teria, such as Odoribacteraceae and Clostridiaceae, were not
observed in any group.
Together, our data suggest that the microbiota, which infil-
trate the gut wall, are likely a major source for excessive suc-
cinate. High succinate is mainly influenced by elevated succi-
nate production but may also be affected by diminished
succinate consumption or a combination of both. This may
lead to high succinate absorption in IBD patients and mouse
models.
DISCUSSION
Succinate was associated with increased invasion of bacteria
into the host tissue that alters bacterial virulence in IBD (Zaidi
et al., 2020) and in Salmonella infection (Rosenberg et al.,
2021). The gut commensals may often invade the host gut tissue
and trigger an immune response that involves the activation of
innate immune cells, such as dendritic cells, macrophages,
and neutrophils, to effectively kill the microbes. An excessive im-
mune response may result in tissue damage, yet a healthy gut is
capable of regenerating a normal and tight barrier. Nevertheless,
genetic or environmental factors hamper the barrier regeneration
in IBD patients, which might stem from local activation of intense
immune responses triggered by either immune cells or epithelial
cells that secrete pro-inflammatory cytokines (Garcia-Carbonell
et al., 2019; Neurath, 2019; Schoultz and Keita, 2019). Impor-
tantly, metabolic changes and particularly elevated cytoplasmic
succinate stimulate pro-inflammatory cytokine secretion. It is
therefore conceivable that continuous elevation of succinate
levels by commensals, pathogens, or host cells will trigger, sus-
tain, or exacerbate a chronic inflammatory response. Here, we
found that transepithelial delivery of succinate to macrophages
is mediated by the SLC13 transporters and regulated by
SLC26 transporters in epithelial cells and macrophages (Figures
1, 2, and 3). Consequently, we show that succinate uptake leads
to a significant and time-dependent elevation in NO secretion by
macrophages that were stimulated with LPS and IFNg. Impor-
tantly, the effect of extracellular succinate uptake on NO secre-
tion wasmonitored in the absence of L-glutamine in the media to
attenuate intracellular succinate production. The perpetuation of
the pro-inflammatory state in macrophages may occur because
of elevation of cytoplasmic succinate that stabilizes HIF (Tanna-
hill et al., 2013).Cell Reports 36, 109521, August 10, 2021 7
Figure 6. The abundance of succinate-metabolizing bacteria in the
colon tissue is disrupted in patients with IBD and in a colitis mouse
model
(A–C) We assessed succinate-producing bacteria (A and B) and succinate-
consuming bacteria (C) in colon tissues using metagenome analysis at the
species level in either IBD patients (A andC) or colitis mousemodels (DSS- and
TNBS-treated) (B) compared with HCs.
Data are shown as means ± SEM. The data were analyzed using one-way
ANOVA followed by a multiple comparisons post-test. *p < 0.05. DSS, treated
with dextran sodium sulfate; OTUs, operational taxonomic units; TNBS,
treated with trinitrobenzene sulfonic acid.
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ogies were implicated with elevated succinate concentrations,
namely, arthritis (Littlewood-Evans et al., 2016) and calcium-ox-
alate kidney stones (Khamaysi et al., 2019; Ohana et al., 2013).
Interestingly, some extraintestinal pathologies were identified
in IBD patients prior to the onset of the gut symptoms (Arvikar
and Fisher, 2011). These observations suggest that although
IBDs are characterized by intense immune responses, the un-
derlying cause may not be immunological in nature. Therefore,
we argue that IBD may be a significant symptom of a broad
metabolic syndrome of hampered succinate homeostasis. An
immediate question that arises is: why does the intestine actively
absorb the pro-inflammatory succinate under physiological con-
ditions? One plausible answer to this question was provided by
De Vadder et al. (2016), who show that normal levels of micro-
biota-produced succinate are necessary to improve glucose ho-
meostasis by gluconeogenesis that takes place in the intestinal
epithelia. Here, we measured succinate concentrations in IBD
patients, as well as mouse models, and found that in IBD, succi-
nate is significantly elevated in the feces and the serum (Figure 5).
These findings may suggest that high luminal succinate in the in-
testine of IBD patients leads to elevated absorption of succinate.
This is further supported by a previous study, which reported
elevated fecal succinate concentrations in human IBD patients8 Cell Reports 36, 109521, August 10, 2021(Hallert et al., 2003) and in an IBD mouse model (Ariake et al.,
2000; Osaka et al., 2017). High serum succinate levels were
also found in obese individuals (Serena et al., 2018). Intriguingly,
obesity is strongly associated with IBD because 15%–40% of
IBD patients are obese (Singh et al., 2017).
Importantly, we also found that the gene expression of
SUCNR1, SLC26A6, SLC26A3, and SLC13A3 were elevated in
the colon of IBD patients (Figures 4C and 4F–4H). These genes
encode proteins that act to lower succinate absorption by regu-
lating apical uptake (SLC26A3, SLC26A6, SUCNR1) or medi-
ating basolateral clearance (SLC13A3). As we show here,
SLC13A3, SLC26A6 (Figures 2C and 2D), and SUCNR1 (Fig-
ure 2A) may also regulate succinate transport in macrophages.
Notably, a strong association was reported in a genome-wide
association IBD study with the SLC26A3 gene (Asano et al.,
2009; Liu et al., 2015). Therefore, in our cohort, the observed up-
regulation of these genes is likely a protective measure to lower
the pathological succinate surge in the colon. In contrast, if the
expression of proteins that regulate succinate transporters is
lowered, as suggested for SLC26A3 in several reports (reviewed
here and by Priyamvada et al., 2015), this may elevate the uptake
of succinate and exacerbate inflammation. In our cohort, we
found that although the protein expression of SUCNR1 is
elevated (Figures 4A and 4B), the expression of SLC26A6 was
lower in the intestine of IBD patients (Figures 4D and 4E). Low
SLC26A6 expression is expected to reduce the inhibition of suc-
cinate uptake by SLC13 transporters and, thus, elevate transepi-
thelial succinate absorption leading to high serum succinate
(Figure 5A). Taken together, our results and previous studies
indicate that changes in the expression of succinate transport
regulating proteins in IBD patients may vary between individuals,
populations, and maybe also during the course of the disease,
but they ultimately lead to elevated succinate flux and
inflammation.
Other metabolites were also implicated with immune
response regulation. For example, the signaling of short-chain
fatty acids (SCFAs), such as acetate, butyrate, and propionate,
via GPR41 and GPR43, as well as other metabolite receptors,
show significant anti-inflammatory effects (Tan et al., 2017).
This suggests that the balance between succinate and SCFAs
or other metabolites may modulate inflammatory processes. It
is, therefore, not surprising that the diet and microbiota compo-
sition play a key role in inflammation. Several bacterial species
produce SCFAs through fermentation of dietary fibers, where
succinate is a product of the microbial metabolic pathway of
the SCFA, propionate, as reported for B. fragilis (Macy et al.,
1978). Remarkably, the most significant dysbiosis we found in
our metagenomic analysis was the elevation of B. fragilis in
the tissue of UC patients (Figure 6A). Several bacteria, including
B. fragilis, were known as typical microorganisms used for
fermentative succinate production (Cao et al., 2013). It was
shown that reconstitution of microbiota-depleted mice with
the succinate-producing commensal, B. thetaiotaomicron,
augmented GI pathophysiology during C. rodentium infection,
enhancing edema of the colonic epithelium, exacerbating crypt
destruction, increasing immune infiltration, and impairing intes-
tinal epithelial repair (Connors et al., 2018; Curtis et al., 2014).
Nevertheless, numerous studies suggest that significant
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patient populations (Ni et al., 2017). Clearly, there is also a very
high variance in gene expression between different IBD popu-
lations (Jostins et al., 2012; Liu et al., 2015). Our findings sug-
gest that the pathology is not a result of a specific gene expres-
sion pattern or the microbiota population, but rather the
manifestation of the metabolite composition in the gut. In other
words, different microbiota compositions can generate high
succinate concentrations that either cause or maintain IBD.
For example, high abundance of succinate-producing bacteria
or, alternatively, low abundance of succinate-consuming bac-
teria is expected to elevate mucosal succinate concentration.
Indeed, a previous metagenomic analysis reported a reduced
abundance of succinate-consuming Phascolarctobacterium
among IBD patients (Morgan et al., 2012). Consistent with
this, we now show a decreased abundance of the succinate-
consuming bacteria P. succinatutens in CD patients (Figure 6C).
This may explain the high fecal succinate we monitored in IBD
(Figures 5B and 5C) and the lack of significant increase in the
abundance of succinate-producing bacteria in our cohort’s
CD patients (Figure 6A; Figures S4 and S5). Subsequently, as
we show here, the transport and signaling pathways on both
epithelial cells and macrophages are required to modulate suc-
cinate homeostasis. Any impairment along these pathways or a
breach of the epithelial barrier can potentially increase succi-
nate concentrations in the macrophages’ extracellular or intra-
cellular milieu, leading to chronic inflammation.
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Limitations of the study
In this study, we have identified the role of specific transporters
in mediating transepithelial succinate uptake and delivery into
macrophages. We also found that determinants within this sys-
tem and succinate-metabolizing microbiota are significantly
altered during IBD. Nevertheless, the function of SUCNR1,
SLC13 transporters, and SLC26 transporters requires further
characterization to determine their precise role in mediating
and regulating succinate homeostasis in macrophages. These
open questions should be addressed in future studies using
in vitro and in vivo systems to determine how impaired function
of succinate signaling and transport systems is associated with
IBD and, potentially, other comorbidities and inflammatory
diseases.
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Antibodies
SUCNR1/GPR91 Novusbio Cat#NBP1-00861
IL-1b Santa Cruz Biotechnology Cat#H-153
donkey anti-goat IgG-HRP Santa Cruz Biotechnology Cat#Sc-2020
CD206 R&D Systems Cat#AF2535
Goat anti-Rabbit IgG (H+L) Cross-
Adsorbed Secondary Antibody, HRP
Thermo Fisher Cat#G21234
b-Actin Sigma-Aldrich Cat#A3854
F4/80 Biogems Cat#02922-80; Clone BM8.1
CD16/CD32 Biogems Cat#08212; Clone 2.4G2
CD11b Biolegend Cat#101215; Clone M1/70
CD80 Biolegend Cat#104725; Clone 16-10A1
SLC26A6 Santa Cruz Cat#sc-515230
SUCNR1 Abbexa Cat#abx318542
Goat anti-Mouse IgG (H+L) Cross-
Adsorbed Secondary Antibody, Alexa Fluor
488
Invitrogen Cat#A-11001




Human fecal samples, serum, gut tissues Severance Hospital N/A
Chemicals, peptides, and recombinant proteins
cOmplete, EDTA-free Protease Inhibitor
Cocktail
Roche Cat#11873580001
Pierce Lane Marker Reducing Sample
Buffer
Thermo Fisher Scientific Cat#39000
Citric acid Sigma-Aldrich Cat#C0759
N-METHYL-D-GLUCAMINE Sigma-Aldrich Cat#M2004
Sodium succinate Sigma-Aldrich Cat#14160
Succinic acid Sigma-Aldrich Cat#S3674
Dextran sulfate sodium (DSS) MP Biomedicals Cat#160110
Chlorophenylalanine Sigma-Aldrich Cat#C6506
2,4,6-trinitrobenzene sulfonic acid (TNBS) Thermo Fisher Scientific Cat#28997





70-mm strainer FLACON Cat#FAL352350
LPS Sigma-Aldrich Cat#L2880
14C-Succinic acid ViTrax Inc Cat#VC 195
3H-Citric acid ViTrax Inc Cat#VT 295
SLC13A5 inhibitor BI01383298 TOCRIS Bioscience CAS#2227549-00-8
TRIzol Thermo Fisher Scientific Cat#15596018
SYBR Green master mix Thermo Fisher Scientific Cat#4368708
Horse serum Vector Cat#S-2000
(Continued on next page)
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DMEM Biological Industries Cat#01-052-1A
L-Glutamine Biological Industries Cat#03-020-1B
Trypsin Biological Industries Cat#03-052-1B
FBS Biological Industries Cat#04-007-1A
Sodium pyruvate Sigma-Aldrich Cat#P5280
PBS Biological Industries Cat#02-023-1A
Critical commercial assays
succinate Colorimetric Assay Kit Sigma–Aldrich Cat#MAK184
cDNA Reverse Transcription Kit Thermo Fisher Scientific Cat#4368813
Griess reagent system Promega Cat#G2930
FastDNA SPIN Kit MP Biomedicals Cat#116560200
Deposited data
microarray analysis data Noubade et al., 2014 GEO: GSE53986
16S rRNA Sequence identification EzTaxon-e database https://eztaxon-e.ezbiocloud.Net
Experimental models: Cell lines
RAW264.7 Schuster et al., 2020 N/A
C2BBe1 Brami et al., 2020 N/A
HEK293T Khamaysi et al., 2019 N/A
Experimental models: Organisms/strains
C57BL/6 mice Orient, Seongnam, South Korea N/A
C57BL/6 mice SLC26A6/ Gift from Prof. Shmuel Muallem; Wang
et al., 2006; Ohana et al., 2013; Khamaysi
et al., 2019
N/A

































Slc13a2 Khamaysi et al., 2019 RefSeq: BC096277
Slc13a3 Khamaysi et al., 2019 RefSeq: BC026803
Slc13a5 Khamaysi et al., 2020 RefSeq: BC143689
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIERR
Slc26a6 Khamaysi et al., 2019 RefSeq: NM_022911
Software and algorithms
LECO Chroma TOF software version 4.44 LECO Corp N/A





SIMCA-P+ version 12.0 Umetrics N/A
CLcommunity software Chunlab Inc N/A
Clampex 10 system Axon Instruments N/A
ImageJ NIH https://imagej.nih.gov/ij/
FACSDiva 8.0.2 BD biosciences N/A
FlowJo 10.7.1 BD biosciences N/A
Prism 6.0 GraphPad Inc https://www.graphpad.com/
scientific-software/prism/
Other
7890 gas chromatography system Agilent Technologies N/A
Agilent 7693 auto-sampler Agilent Technologies N/A
Pegasus HT TOF MS LECO Corp N/A
Rtx-5MS column Restek Corp N/A
Vibra-cell Sonicator SONICS VCX130
speed vacuum concentrator Biotron Modulspin 31
454 GS FLX Titanium Sequencing Systems Roche N/A
Packard 1900CA TRI-CARB Packard N/A
Amplifier Warner Instrument Corporation OC-725C
A/D converter Axon Instruments Digidata 1550A
Microscope Olympus Optical BX41
real-time PCR Applied Biosystems StepOne Plus
FACSAria III Becton Dickinson N/A
VERSAmax tunable microplate reader Molecular devices N/A





Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Ehud
Ohana (ohanaeh@bgu.ac.il).
Materials availability
This study did not generate new unique reagents.
Data and code availability
d All data reported in this paper will be shared by the lead contact upon request.
d This paper does not report original code.
d Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.e3 Cell Reports 36, 109521, August 10, 2021
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Human volunteers
Healthy volunteers (HC), Crohn’s disease (CD) and ulcerative colitis (UC) patients of Korean heritage,were recruited atSeveranceHospital
(Yonsei University College of Medicine, Seoul, Korea). The Clinical and demographic characteristics of the volunteers are elaborated in
Figure S3 (table 3). The Institutional Review Board of Severance Hospital, Yonsei University approved this study (IRB approval number:
4-2012-0302). All patients and controls provided written informed consent, and all methods were performed in accordance with the rele-
vant guidelines and regulations. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination of our
research. FigureS3At all times, diagnosis ofCDandUCwasmadeaccording to previously established international criteria basedonclin-
ical, endoscopic, histopathological, and radiological findings (Nikolaus and Schreiber, 2007).
Animal models
All the work on mice and Xenopus laevis were approved by the Institutional Animal Care and Use Committee of the Ben Gurion Uni-
versity of the Negev, Israel (IACUC Approval No: IL-80-10-2019 and IL-83-10-2019) or Yonsei University Severance Hospital, Seoul,
Korea (IACUC Approval No: 2014-0299). Colitis was induced in 8-week-old male C57BL/6 mice (Orient, Seongnam, South Korea)
using DSS (2.5%, MP Biomedicals, Solon, OH, USA) or TNBS (Thermo Fisher Scientific, Pittsburgh, PA, USA), as previously
described (Kim et al., 2019; Seo et al., 2017). A piece of the colons was used formetagenome analyses. All experiments using animals
were carried out in accordance with the approved guidelines by the IACUC.
Peritoneal and bone marrow-derived macrophages (BMDM) were isolated from either SLC26A6/ mice (Khamaysi et al., 2019;
Ohana et al., 2013; Wang et al., 2006) or wild-type (WT) littermates, as described later.
Cell cultures and transwell system
Primary BMDM were cultured with DMEM enriched with 10% FBS, 5% L-Glutamine and pen-strep (Biological Industries, Israel),
1 mM Na-pyruvate (BMDM media). RAW264.7 cells (Schuster et al., 2020) were cultured in DMEM enriched with 10% FBS, 5%
L-Glutamine and pen-strep. C2BBe1 cells (Brami et al., 2020) were cultured under similar conditions as RAW264.7 cells with the
exception of adding 0.01 mg/ml human transferrin. Collagen coated transwells (corning) were inserted in 12-well plates and incu-
bated with DMEM. Next, Caco-2 cells and macrophages were seeded in the apical and basolateral poles, respectively. The Caco-2
culture media was replaced every 3 days during 18 to 21 days of culture.
Bone marrow-derived and peritoneal macrophages
Hematopoietic stem cells were extracted from the femur and the tibia of 8 to 16 weeks old mice, as previously described (Amend
et al., 2016). Harvested cells were cultured with 20ng/ml M-CSF (peprotech, Israel) 7 days. The remaining BMDM cells were then
stimulated for 48 hours with either BMDM media alone or in the presence of 10ng/ml LPS and 20 ng/ml IFNg or 20 ng/ml IL4/
IL13. For peritoneal cells isolation, mice were injected with thioglycolate (2% v/v, i.p., 1.5 ml per mouse). Four days later, peritoneal
lavagewas performedwith ice cold PBS. Cells were then filtered through a 70-mmsterile nylon strainer and seeded in DMEMmedium
supplemented with 10% FCS, 50 units/ml penicillin, and 50 mg/ml streptomycin. Twenty-four hours later, the cells were stimulated
with 10ng/ml LPS and 20 ng/ml IFNg for additional 24 hours.
METHOD DETAILS
Succinate assay of fecal samples
Succinate assay of fecal samples of healthy controls (HC), patients with Crohn’s disease (CD) and with ulcerative colitis (UC), normal
mice, and 2.5% dextran sulfate sodium (DSS)-treated mice with colitis was performed using succinate Colorimetric Assay Kit
(MAK184, Sigma–Aldrich, MO, USA) according to the manufacturer’s protocol.
Succinate evaluation of serum samples
Metabolites were extracted from 200 mL of serum of healthy controls, patients with CD and with UC. A solution of 600 mL of methanol
and 10 mL of an internal standard solution (2-chlorophenylalanine, 1 mg/mL in water) was added to the serum and then homogenized
using a sonicator for 5 min. After homogenization, the suspension was held at 20C for 60 min, and then centrifuged at 12,000 rpm
and 4C for 10min. The supernatant was filtered through a 0.2-mmfilter and dried using a speed vacuum concentrator (Modulspin 31;
Biotron, Korea). Dried extracts were re-dissolved in 250 mL ofmethanol, and 100 mL of the sampleswere dried under a vacuum for gas
chromatography (GC)–TOF–MS analysis.
For GC–TOF–MS analysis, dried samples were oximated with 50 mL of methoxyamine hydrochloride (20 mg/mL in pyridine) for
90 min at 30C and silylated with 50 mL of N-methyl-N-(trimethylsilyl) trifluoroacetamide for 30 min at 37C. GC–TOF–MS analysis
was performed using an Agilent 7890 gas chromatography system (Agilent Technologies, Palo Alto, CA, USA) coupledwith an Agilent
7693 auto-sampler (Agilent Technologies) and equippedwith a PegasusHT TOFMS (LECOCorp., St. Joseph,MI, USA) system. An
Rtx-5MS column (i.d., 30 m 3 0.25 mm, 0.25 mm particle size; Restek Corp., Bellefonte, PA, USA) was used with a constant flow
of 1.5 mL/min of helium as the carrier gas. Samples (1 mL aliquots) were injected into the GC with the splitless mode. The ovenCell Reports 36, 109521, August 10, 2021 e4
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atures of the front inlet and transfer lines were 250 and 240C, respectively. The electron ionization was carried out at 70 eV and full
scanning over the range of 50–1000 m/z was used for mass data collection.
The GC–TOF–MS data were acquired and preprocessed using the LECO Chroma TOF software (version 4.44, LECO Corp.) and
converted into the NetCDF format (*.cdf) using the LECO Chroma TOF software. After conversion, peak detection, retention time
correction, and alignment were processed using the Metalign software package (https://www.wur.nl/nl/Onderzoek-Resultaten/
Onderzoeksinstituten/food-safety-research/show-wfsr/MetAlign.htm). Multivariate statistical analysis was conducted using
SIMCA-P+ (version 12.0; Umetrics, Umeå, Sweden). The dot plots of the mean of triplicate measurements were rendered using
the relative peak area of unique masses of succinate by Prism 5.0 Software (GraphPad Inc. San Diego, CA, USA).
Evaluation of microbiota changes by pyrosequencing
Total DNA from normal and inflamed colon tissues and feces of either healthy controls or IBD patients was isolated using FastDNA
SPIN Kit for Soil kit (MP Biomedicals) according to the manufacturer’s recommendation. Samples were collected from healthy con-
trols, CD patients and UC patients. In addition, samples were collected from normal-water supplied mice, DSS-treated mice, and
2,4,6-trinitrobenzene sulfonic acid (TNBS)-treated mice. For pyrosequencing, amplification of genomic DNA was performed using
barcoded primers that targeted the V3–V4 region of the bacterial 16S rRNA gene. The amplification, pyrosequencing, and basic anal-
ysis were performed according to the methods described by Chunlab Inc. (Seoul, Korea) (Chun et al., 2010) using a 454 GS FLX Ti-
tanium Sequencing Systems (Roche, Branford, CT, USA). Sequence reads were identified using the EzTaxon-e database (https://
eztaxon-e.ezbiocloud.net/) on the basis of 16S rRNA sequence data. We analyzed operational taxonomic units (OTUs) and assessed
beta diversity using principal coordinate analysis (PCoA) and alpha-diversity analysis using the diversity index (Chao1, Shannon, and
Simpson index). Bacterial community abundance was generated using the CLcommunity software (Chunlab Inc.).
The OTUs for either succinate-producing or succinate-consuming bacteria were analyzed to evaluate the abundances of different
species as indicated.
Protein expression analysis by western blotting
Cell lysates were prepared by incubating the cells in an ice-cold lysis buffer containing PBS, 10mMNa+ pyrophosphate, 50mMNaF,
1mMNa+ -orthovanadate, 1%Triton X-100, and a cocktail of protease inhibitors (Roche, Basel, Switzerland). Cells were suspended,
sonicated and centrifuged. Lysates were collected and stored in SDS sample buffer. Samples were subjected to SDS-PAGE and
transferred to nitrocellulose membranes (GE Whatman, Pittsburgh, PA, USA), for which western blot analysis was performed. The
nitrocellulose membranes were incubated overnight with either polyclonal anti-SUCNR1, (Novusbio, Littleton, CO, USA), anti-IL-
1b (Santa Cruz Biotechnology, Dallas, TX), anti-CD206 (R&D Systems, Minneapolis, USA) or anti–b-actin antibodies.
Succinate and citrate uptake measurements
On the day of the experiment, the cells were washed with a solution that contained or lacked Na+ (in mM): 5 mM KCl, 10 mMHEPES,
10 mM glucose and 140 mM NMDG-Cl (Na+-free) or NaCl, pH7.4. Subsequently, the incubation solution was supplemented with ra-
diolabeledmetabolites (ViTrax Inc., Placentia, CA, USA) as follows: 1mMsuccinic acid, and 1 mCi 14C-succinic acid per 1.6 mmol cold
succinate or 3mM citric acid and 1 mCi 3H-citric acid per 3 mmol cold citric acid. The ‘hot’ incubation solutions were added to the cells
in the Na+-containing (NaCl) or Na+-free (NMDG-Cl) solution. The SLC13A5 inhibitor BI01383298, 1-(3,5-Dichlorophenylsulfonyl)-N-
(4-fluorobenzyl)piperidine-4-carboxamide (TOCRIS Bioscience, Bristol, UK) was used at a final concentration of 10 mM. The cells
were then washed twice, and NaOH (1 M) was immediately added to lyse the cells. The lysates were then transferred to scintillation
vials containing HCl (1 M). Finally, radioactivity was determined by liquid scintillation counting using a Packard 1900CA TRI-CARB
analyzer. The osmolarity of all solutions was adjusted to 300 mOsm with the major salt.
Preparation and injection of oocytes
All the work on Xenopus laeviswas approved by the Institutional Animal Care and Use Committee of the Ben Gurion University of the
Negev. Oocytes were obtained by a partial ovariectomy of female Xenopus laevis (XenopusOne, Dexter, MI), as previously described
(Shcheynikov et al., 2004). Briefly, the frogs were anesthetized and follicle cells were removed in an OR-2 calcium-free medium. The
defolliculated oocytes were washed with OR-2 calcium-free medium and healthy oocytes in stages V to VI were identified, collected
under binoculars and maintained overnight at 18C in an ND96 solution. 32 nL of the different cRNA were injected into the oocytes
using a Nanoliter 2010 injector (World Precision Instruments, Inc., Sarasota, FL). Similar volumes and concentrations (4 mg/ml) of
cRNA or water were mixed to achieve similar amounts of injected cRNA per oocyte. The oocytes were incubated at 18C in an
ND96 solution with pyruvate and antibiotics and were studied 48–96 h after cRNA injection. The use of several oocyte batches
may result in functional variance as we observed. To overcome this technical obstacle wemonitored the currents in oocytes injected
with either water or SLC13A3 in the absence or presence of slc26a6 and summarized the data for each batch.
Voltage and current measurement in oocytes
Voltage and current recordings were performed with a two-electrode voltage clamp as described (Hong et al., 2013). The current was
recorded with a Warner Instrument Corporation amplifier model OC-725C (Hamden, CT) and digitized via an A/D converter (Digidatae5 Cell Reports 36, 109521, August 10, 2021
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to record and control themembrane potential. Datawere analyzed using the Clampex 10 system (Axon Instruments, Inc.). The following
solutions were used as indicated in the figures: Standard HEPES-buffered ND96 oocyte regular medium containing (in mM): 96 NaCl, 2
KCl, 1.8 CaCl2, 1 MgCl2, and 5 HEPES, pH = 7.5. Na
+-succinate was added to the solutions as indicated in the figures.
Immunohistochemistry and immunofluorescent staining
Immunohistochemistry (IHC) was performed using the following antibodies: anti-human SUCNR1 (1:200; Abbexa, Cambridge, UK),
anti-human SLC26A6 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA). High-temperature antigen retrieval was performed
by immersing the slides in a water bath at 95–98C in a 10 mM trisodium citrate buffer (pH 6.0) for 45 min. Nonspecific binding was
blocked by incubating sections for 1 h with normal horse serum (Vector, Bretton, UK) diluted in PBS. Samples were blocked for endog-
enous peroxidase activity using 1% H2O2 in IHC. After overnight incubation at 4
C with primary antibodies, slides were washed with
PBS and incubated with anti-rabbit 1:500 or anti-mouse 1:500 secondary antibodies (Santa Cruz Biotechnology), as previously
described (Seo et al., 2017). The nuclei were counterstained with 4’-6-diamidino-2-phenylindole (DAPI) in immunofluorescent staining.
Images were obtained using a microscope (Olympus BX41; Olympus Optical, Tokyo, Japan). Densitometric analysis was performed
using ImageJ software (NIH, Bethesda, MD, USA).
Quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR)
Total RNAwas extracted from human colon biopsies using TRIzol Reagent (Thermo Fisher Scientific, MA, USA), and 1 mg of RNAwas
reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) according
to the manufacturer’s protocol. The cDNAs were mixed with SYBR Green master mix (Applied Biosystems) and pairs of primers
(200 nmol of each primer, final concentration) in duplicate. Real-time PCR primers are as follows: Human SLC26A6: forward
50-CACCTCCCGGTTTTGGTCTG-30, reverse 50-CAGGCCGGATAACAGGTCAC-30; human SLC26A3: forward 50-AGATGCCCCAC-
TACTCTGTCCT-30, reverse 50-ATCCACACCACACCTCTGCTT-30; human SLC13A3: forward 50-CTTCATGCTCCCGGTCTCAAC-
30, reverse 50-GCCCAGGTATTCATAGCCAAA-30; human SUCNR1: forward 50-GGAGACGTGCTCTGCATAAG-30, reverse 50-AGGTG
TTCTCGGAAAGGATACTT-30; human b-ACTIN: forward 50-hCTCTTCCAGCCTTCCTTCCTG-30, reverse 50-CAGCACTGTGTT
GGCGTACAG-30. Samples were amplified in a StepOne Plus real-time PCR system (Applied Biosystems) for 45 cycles using the
following PCR scheme: 95C for 30 s, 58‒61C for 30 s, and 72C for 40 s. Finally, gene expression levels were calculated using
the relative comparative method using the following equation: relative gene expression = 2-(DCt sample–DCt control) and results were re-
ported as the fold change compared to the calibrator or 2DCt after normalization of the transcript level to the average of the endog-
enous control, b-ACTIN.
Flow Cytometry
To analyze cell surface expression of Macrophages polarization we harvested cells using Versena Solution (Life Technologies, CA,
USA). Blocking was done using 1mg/ml anti-mouse CD16/CD32 (Clone 2.4G2, Biogems, CA, USA) for 10 minutes. Surfaces staining
was done using 1-2mg/ml of the following antibodies; Anti-Mouse F4/80 APC (Clone BM8.1, Biogems, CA, USA), Anti-Mouse CD11b
PE-Cy7 (Clone M1/70, Biolegend, CA, USA), Anti-Mouse CD80 BV421 (Clone 16-10A1, Biolegend, CA, USA) in staining buffer con-
tains 1x PBS, 2%Fetal Bovine Serum, 0.05%SodiumAzide for 40minutes on ice. Cells were washedwith 1x PBS and analyzed using
FACSAria III (Becton Dickinson, CA, USA) with appropriate detectors voltage and compensation adjustments (Software version
FACSDiva 8.0.2). Samples viability (dead cells < 5%) was verified in separate sample using Propidium Iodide staining in separate
tube. Data were analyzed and plotted using FlowJo (FlowJo LLC, OR, USA).
Nitric Oxide (NO) quantification assay
NOconcentrationsweremeasured inmedia collected fromeither BMDMor RAW264.7macrophages cultures. Briefly, themacrophage
cultures were either stimulated by 10 ng/ml LPS, 20 ng/ml IFNg, and 5mMNa+-succinate or vehicle alone (naive), and incubated for 16
hours. Subsequently, the cultures were washed with growth media containing either NaCl or Na+-succinate and incubated for 50 h.
During the incubation period, 65 mL of media were collected for NO analysis at different time points, as indicated in Figure 1E. The
collected media samples were centrifuged for 5 min at 10,000 RPM and the supernatants were stored at 20C. A colorimetric Griess
reagent system (Promega, Maddison, WI, USA) was utilized tomonitor NO (NO2
-) concentrations, according to themanufacturer’s pro-
tocol. Colorimetric measurements were performed using the VERSAmax tunable microplate reader (Molecular devices).
QUANTIFICATION AND STATISTICAL ANALYSIS
Prism Software (ver 5.0 and 6.0) (GraphPad Inc. San Diego, CA, USA) was used for statistical data analyses, with a two-tailed Stu-
dent’s t test or Mann-Whitney. For three or more groups we performed normality tests followed by the appropriate ANOVA multiple
comparison tests (Tukey’s, Kruskal-wallis or Dunn’s). The P values, tests and statistical significance are described in the figure leg-
ends and figures. All N represent either individual samples from different patients or mice, individual wells for cell culture experiments
or individual cells in the Xenopus oocytes experiment (Figure 2E).Cell Reports 36, 109521, August 10, 2021 e6
